Baxter Launches Hemopatch Sealing Hemostat with Room Temperature Storage Across Europe
New enhancement improves on-demand access in the operating room
Baxter International Inc. (NYSE: BAX), a global leader in advancing surgical innovation, today announced the European launch of its Hemopatch™ Sealing Hemostat with room temperature storage. Introduced at a surgical symposium in Austria, this next-generation evolution enhances operating room accessibility by eliminating the need for refrigeration—enabling immediate use during critical procedures.
This development stems from close collaboration with surgeons to better address their evolving needs and further support optimal patient care.
“For more than a decade, Hemopatch has been a trusted solution for surgeons requiring reliable tissue sealing, dura sealing, and hemostasis,” said Steve Wallace, president of Advanced Surgery at Baxter. “The transition to room temperature storage reflects our commitment to partnering with the surgical community. It allows hospitals to keep Hemopatch readily available without refrigeration—streamlining workflows and improving readiness for urgent surgical needs.”
Hemopatch is a ready-to-use, absorbable collagen pad designed for effective and safe use in both open and minimally invasive procedures. It has demonstrated rapid and sustained hemostasis across various surgical specialties, supported by real-world data from clinical use throughout Europe.¹
Prof. Dr. med. Selman Uranüs, a general surgeon and early adopter of Hemopatch, shared:
“Over ten years ago, I participated in the initial testing of Hemopatch and have used it consistently since then, especially in laparoscopic surgeries. Its unique sealing and hemostatic properties have been invaluable in my practice. The new room temperature storage format and extended shelf life represent significant advancements, ensuring the product is available exactly when needed in the OR. Its enhanced adhesive strength further supports improved surgical outcomes.”²
The Hemopatch Sealing Hemostat with room temperature storage is now available to order across Europe.
About Hemopatch Sealing Hemostat
Hemopatch Sealing Hemostat consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate). Due to its flexible structure, the application of Hemopatch Sealing Hemostat to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.3
About Baxter
Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
INDICATIONS
Hemopatch Sealing Hemostat is indicated as a hemostatic device and surgical sealant across various soft tissues (cardiovascular, connective tissue, parenchyma, serosa, viscera), and dura for procedures in which control of mild or moderate bleeding or leakage of other body fluids or air by conventional surgical techniques is either ineffective or impractical. Hemopatch Sealing Hemostat may be used to augment dura closure techniques to close small dural defects (≤3mm) following traumatic injury, excision, retraction or shrinkage of the dura mater.
